Clinical Trial

IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an investigator-initiated, single-arm, open-label clinical study. It employs a dose-escalation design to evaluate the safety, pharmacokinetics, and preliminary efficacy of IASO208 injection in relapsed/refractory B-cell malignancies.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-15; most recent amendment 2026-05-27.
Status change: Not Yet Recruiting → Recruiting 2026-01-08
Trial Details
NCT Number NCT07309900
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators: Shanghai IASO Biotechnology Co., Ltd
Conditions Relapsed/Refractory B-cell Malignancies
Enrollment 12 participants
Start Date 2025-11-21
Primary Completion 2028-12-15 (estimated)
Study Completion 2029-06-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-01